bolsia
Portfolios
Blog
Forex
Clubs
Forum
Groups
Login
Registrarse
IBEX
8,231
-1.69%
EUROSTOXX50
3,600
-1.15%
FTSE
5,510
-5.25%
DAX
9,633
-3.68%
Stocks
Portfolios
Portfolios
Stocks
Recent Trades
Bolsia Coins
Referrals
FAQs
US Stocks
Buy Stocks
Chart
Maximum Portfolio Game:
25%
Company
Quote
Time
Celgene Corp. (CELG)
$64.15
(0.00%)
22:00
(31/12/2018)
Portfolios Holding
CELG
Alrexx 395.8%
Letmark 238.0%
Oscartarraco 58.1%
RMOONU 53.8%
Dscdsc 52.1%
ALBERTOJA 41.8%
Oscarsa 31.9%
BokerL 16.3%
News
Celgene Corp Issues FY 2013 Guidance In Line With Analysts' Estimates; Reaffirms FY 2015 Guidance; Issues FY 2017 Guidance
CELGENE CORPORATION : Celgene Outlines Plan for New Growth Phase
Celgene Says Pancreatic Cancer Drug Extends Life by Nearly 2 Months
InterMune Inc., Novartis, Celgene Corporation, Targacept Inc. and Agenus Inc ...
UPDATE: BMO Capital Markets Reiterates Outperform Rating, Raises PT on ...
UPDATE: Piper Jaffray Upgrades Celgene Corporation to Overweight on ...
Celgene Corporation Presents at 31st Annual JPMorgan Healthcare Conference ...
CELGENE CORPORATION : Celgene Sees 2012 Earnings at High End of View
Celgene Corporation Announces Financial Outlook and Preliminary 2012 Results
Celgene Corp. Now #88 Largest Company, Surpassing Biogen Idec
Trading Analysis for Celgene Corporation (CELG)
Senior Director, Clinical RD (MD), Oncology Job
Celgene Corporation to Present at the 31st Annual JP Morgan Healthcare ...
Senior Director, Lead Global Product Safety Physician Job
Celgene Corporation to Present at the 31st Annual JP Morgan Healthcare ...
Sutro Biopharma Collaborates with Celgene Corporation to Design and Develop ...
Celgene Corp Raises FY 2012 EPS Guidance; Narrows FY 2012 Revenue Guidance To A Range In Line With Analysts' Estimates
Celgene Corp's Abraxane Improved Pancreatic Cancer Survival In Trial-Reuters
Celgene Corp Sees FY 2012 Revenue Guidance At Low End Of Prior Range; Issues FY 2015 Guidance In Line With Analysts' Estimates-Conference Call
Celgene Corp Announces Results From Study Evaluating Combination Of REVLIMID (lenalidomide) plus VIDAZA (azacitidine)